Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNEL FE 1.5/30 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years who desire contraception and have not responded to topical therapy)
Prevention of pregnancy
One tablet orally once daily, each tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets).
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norethindrone: 6-12 hours (terminal, multidose); ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; missed doses may reduce contraceptive efficacy.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol: primarily metabolized via CYP3A4; norethindrone: primarily reduced and conjugated, with CYP3A4 involvement.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: 30-50% (norethindrone metabolites), 20-40% (ethinyl estradiol metabolites); biliary/fecal: 20-30% (norethindrone), 30-50% (ethinyl estradiol). Conjugated metabolites excreted in bile and undergo enterohepatic recirculation.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norethindrone: 60-80% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin (specific binding to SHBG not significant).
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: 2-4 L/kg; ethinyl estradiol: 5-10 L/kg. Clinical meaning: Indicates extensive tissue distribution and slow clearance; Vd may increase in obesity.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: Norethindrone ~60-70% (first-pass metabolism); ethinyl estradiol ~40-50% (presystemic conjugation in gut and liver).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No specific dose adjustment provided in labeling; use with caution in patients with renal impairment. GFR-based modifications not established.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in patients with hepatic impairment (Child-Pugh class B or C) or active liver disease. No specific dose adjustment for mild impairment; use with caution.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not indicated for use before menarche. In post-menarche adolescents, dosing is the same as adults: one tablet daily for 21 days, then 7 days placebo.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use in postmenopausal women; no specific geriatric dosing considerations.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women >35 years who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI),Hepatic neoplasia risk,Liver disease (e.g., jaundice, hepatitis),Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolic effects,Ocular lesions (e.g., retinal thrombosis),Menstrual irregularities/breakthrough bleeding,Use in pregnancy (should be ruled out before initiation),Depression
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer or other estrogen-sensitive neoplasia,Benign or malignant liver tumor (current or history),Hepatic adenoma or carcinomas,Active liver disease with abnormal function tests,Major surgery with prolonged immobilization,Diabetes with vascular involvement,Uncontrolled hypertension,Migraine with focal neurological symptoms (current or history),Smoking in women >35 years
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No specific food interactions are reported. However, grapefruit juice may increase ethinyl estradiol levels but interaction is considered weak; avoid excessive grapefruit juice consumption. Ferrous fumarate may reduce absorption of tetracycline antibiotics if taken together; space doses by at least 2 hours. No dietary restrictions are required.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
First trimester: Inadvertent use does not increase risk of major birth defects. Second and third trimesters: Avoid use due to risk of fetal harm from estrogenic and progestogenic effects, including potential genitourinary tract abnormalities. Postnatal effects: Possible long-term neurodevelopmental impacts reported in animal studies.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Excreted in breast milk in small amounts; M/P ratio for ethinyl estradiol approximately 0.04–0.30. Progestin M/P ratio variable. May reduce milk production and quality. Use only if necessary and with caution, especially in early postpartum period.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Contraindicated during pregnancy; no dose adjustment exists. Discontinue immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are not applicable as drug is not used.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Junel Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 mcg and norethindrone 1.5 mg, with ferrous fumarate as placebo. Consider starting on first day of menses or first Sunday after onset. Missed pills increase pregnancy risk; if missing one pill, take as soon as remembered. For missed two pills in week 1 or 2, take two pills daily for two days and use backup contraception. If missed in week 3, consider finishing current pack and skipping placebo, or starting new pack the next day. Drug interactions include rifampin, certain anticonvulsants, and St. John's wort, which may reduce efficacy. Monitor for DVT, PE, stroke, and MI, especially in smokers over 35, hypertensive, diabetic, or obese patients.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time; do not skip days.,If you miss a pill, refer to the package instructions or ask your healthcare provider.,Use backup contraception (e.g., condoms) if you miss pills or start late.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek emergency care for severe abdominal pain, chest pain, leg swelling, or vision changes.,Smoking increases risk of serious cardiovascular effects; avoid smoking, especially if over 35.,Iron supplements are included; ferrous fumarate in placebo tablets is not effective for contraception.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNEL FE 1.5/30 vs ALYACEN 1/35, answered by our medical review team.
JUNEL FE 1.5/30 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNEL FE 1.5/30 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNEL FE 1.5/30 is: One tablet orally once daily, each tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets).. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNEL FE 1.5/30 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNEL FE 1.5/30 is classified as Category C. First trimester: Inadvertent use does not increase risk of major birth defects. Second and third trimesters: Avoid use due to risk of fetal harm from estrogenic and progestogenic e. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.